Jefferies Global Healthcare ConferenceJune 2, 2015

2 K I T E P H A R M A , I N C .2

Forward Looking Statements / Safe Harbor

To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc. (“Kite,”“we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or ourindustry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated bysuch statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,”“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, andsimilar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in thispresentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product developmentactivities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research anddevelopment activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19and any other product candidates; (iv) our ability to obtain funding for our operations and further development andcommercialization of our product candidates; (v) our plans to research and discover additional product candidates, includingthrough our acquired subsidiary in Amsterdam; (vi) our ability to develop, manufacture and commercialize our productcandidates; (vii) the size and growth potential of the markets for our product candidates, and our ability to serve those markets;(viii) the rate and degree of market acceptance of our product candidates; (ix) our ability to attract and retain key scientific ormanagement personnel; (x) the anticipated timing of clinical data availability; and (xi) our expectations regarding our ability toobtain and maintain intellectual property protection for our product candidates. Various factors may cause differences betweenKite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission,including without limitation in its Form 10-Q for the quarter ended March 31, 2015. Except as required by law, we undertake noobligation to publicly update any forward-looking statements, whether as a result of new information, future events orotherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there beany sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration orqualification under the securities laws of any such state or jurisdiction.

3 K I T E P H A R M A , I N C .3

Before Treatment 6 Months After

Treated with anti-CD19 CAR

1985

1995

2005

2015

Before After

Treated with LAK cells + IL-2

30 Years of Cancer Cellular Immunotherapy

4 K I T E P H A R M A , I N C .4 Scans from Dr. Rosenberg NCI

Before Treatment Post Treatment

Ongoing Complete Response 15+ months in a patient with

chemo-refractory PMBCL

A patient with recurrent DLBCL post-SCT treated

with anti-CD19 CAR T cells

Dramatic Response with Anti-CD19 CAR

5 K I T E P H A R M A , I N C .5

Kite is Redefining Cancer Therapy with Gene-based Cellular Immunotherapy

• Corporate Headquarters in Santa Monica, CA and EU R&D facility in Amsterdam, NL

• First product, KTE-C19 projected to launch in 2017

• Robust pipeline of Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) products with multiple products in clinical trials

• Strong IP Estate for CAR and TCR products

• Strategic partnerships providing access to targets, technologies and faster time to human POC data

• Proprietary, low-cost and rapid manufacturing process

Ongoing Response 4+ years in a patient with Follicular Lymphoma

6 K I T E P H A R M A , I N C .6

Experienced Senior Leadership with Proven Track Records for Success

Arie Belldegrun, MD, FACS Founder, Chairman, President, CEO

Cynthia M. Butitta, MBA COO and CFO

David D. Chang, MD, PhD CMO and EVP, R&D

Helen S. Kim, MBA EVP, Business Development

Margo R. Roberts, PhD Chief Scientific Officer

Ton N. M. Schumacher, PhD Chief Scientific Officer, Kite EU

7 K I T E P H A R M A , I N C .7

Scientific Advisory Board: World Leaders in Cancer Immunotherapy

Owen Witte, MD – Chair• Distinguished Professor of Microbiology,

Immunology and Molecular Genetics, UCLA

• Howard Hughes Investigator

• Member, National Academy of Sciences

James Economou, MD, PhD• Professor of Surgery, Microbiology,

Immunology and Molecular Genetics and Molecular and Medical Pharmacology, UCLA

• Vice Chancellor of Research, UCLA

Donald Kohn, MD• Professor of Microbiology, Immunology and

Molecular Genetics & Pediatric Hematology/Oncology, UCLA

• Director, Human Gene and Cell Therapy Program, UCLA

• Member, Broad Stem Cell Research Center & Jonsson Comprehensive Cancer Center

Ronald Levy, MD• Robert K. Summy and Helen K. Summy

Professor of Medicine, Stanford University

• Director, Lymphoma Program, Stanford University

• Member, National Academy of Sciences

Antoni Ribas, MD, PhD• Director, Tumor Immunology Program,

Jonsson Comprehensive Cancer Center, UCLA

• Professor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology, UCLA

Inder Verma, PhD• Irwin and Joan Jacobs Chair of Exemplary

Science and American Cancer Society Professor of Molecular Biology, The Salk Institute

• Member, National Academy of Sciences

8 K I T E P H A R M A , I N C .8

Building a Robust IP Estate with Scientific Leadersin Gene-Based Cellular Immunotherapy

Inve

nto

rsC

linic

al P

ion

ee

r Steven Rosenberg, MD, PhD

• Chief of Surgery, NCI

• Professor of Surgery, Uniformed Services University of Health Sciences and George Washington University School of Medicine and Health Sciences

Margo R. Roberts, PhD

• Chief Scientific Officer, Kite Pharma, Inc.

• Inventor on 16 US patents and patent applications related to CAR T cell technology and tumor vaccine therapies

Zelig Eshhar, PhD

(Member, Kite Scientific Advisory Board)

• Chairman of Immunology Research, Sourasky Medical Center, Tel Aviv

• Professor Emeritus, Weizmann Institute of Science, Israel

9 K I T E P H A R M A , I N C .9

Expanding Pipeline Through Strategic Collaborations and Internal R&D

CRADA•Pioneering research/pipeline

•Product & process design

•Early clinical evaluation

Fully Integrated Company

Strategic Collaboration•Rights to Next Generation TCR

•Access to Manufacturing

•Early clinical evaluation

•9 clinical programs

•Technology platform

•US and EU R&D capabilities

•Clinical and commercial manufacturing

10 K I T E P H A R M A , I N C .10

Engineered Autologous T Cell Therapy (eACT™)

Elegant Science, Streamlined Manufacturing

Kochenderfer and Rosenberg, Nature Reviews Clinical Oncology, 2013

1. Cell Harvest

2. Patient Conditioning

3. Single CAR Cell Infusion

11 K I T E P H A R M A , I N C .11

PROGRAM INDICATION PRE-IND PHASE 1 PHASE 2/3

Anti-CD19 CAR B Cell Malignancies

KTE-C19 CAR

NHL (DLBCL)

NHL (MCL)

CLL

ALL

EGFRvIII CAR Glioblastoma

NY-ESO-1 TCR Solid tumors

MAGE A3/A6 TCR Solid tumors

MAGE A3 TCR Solid tumors

HPV-16 E6 TCRCervical and Head

& Neck CancerHPV-16 E7 TCR

SSX2 TCR Solid tumors

Neo-Antigen TCRs Solid Tumors

Amgen

Collaboration

Heme Malignancies

and Solid Tumors

Multiple CAR and TCR programs in Clinical Testing

Pivotal studies across 4 indications in 2015

Heme Malignancy

Solid Tumors

Other than the KTE-C19 and Amgen related programs, the clinical trials are being conducted by the NCI pursuant to our CRADA.

12 K I T E P H A R M A , I N C .12

IP Portfolio of Greater than 100 Patent Assets Worldwide*

*Includes in-house and in-licensed granted patents and pending patent applications

Broad CAR IPProprietary CARsProprietary TCRsProprietary scFvs

Proprietary Manufacturing TechniquesProprietary T-Cell Selection Techniques

13 K I T E P H A R M A , I N C .13

Kite CAR & TCR PlatformsRedirecting Immune Cells Against Cancer

Chimeric Antigen Receptor (CAR) Products T Cell Receptor (TCR) Products

Targets moleculeson the cell

surface

Targets molecules at or below the

cell surface

14 K I T E P H A R M A , I N C .14

TCR Platform Provides Access to a Broad Spectrum of Therapeutic Tumor Targets

Potential CAR targets(~27% Human Proteome)

Potential TCR targets(~73% Human Proteome)

Sallman et al, BMC Biology (2009)

15 K I T E P H A R M A , I N C .15

Franchise Approach to TCR Platform and Pipeline

NY-ESO-1

HPV-16 E6

Personalized

MAGE A3 MAGE A3/A6

•Uniquely expressed only on cancer cells

Cancer Testis

Antigens

•Viral antigens are unique

•High-risk oncogenic virusesViral

Antigens

• Specific to a patient’s own tumor

Neo-antigens

Proprietary Platform Allowing Rapid, High-throughput Identification of TCR-Based Product Candidates

SSX2

HPV-16 E7

Targets

16 K I T E P H A R M A , I N C .16

TCF Acquisition Expands TCR Product Pipeline in Solid Tumors

HIGHLIGHTS OF ACQUISITION

• TCR-GENErator™: industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates, which could enter the clinic as early as 2017.

• NKI Relationship: provides important operational platform, access to investigators, clinical sites and manufacturing facilities in Europe.

• Professor Dr. Schumacher: preeminent scientist in immunotherapy to lead Kite Pharma EU as CSO

• European presence

17 K I T E P H A R M A , I N C .17

Actively Investigating CARs and TCRs that Target Multiple Tumor Types

CD19

EGFRvIII

HPV-16 E6

NY-ESO-1

HPV-16 E7

MAGE A3

MAGEA3/A6

SSX2

Neo-Antigens

Non-Hodgkin Lymphoma and Leukemias

Glioblastoma, Head and neck cancer, Melanoma

Head and neck cancer, Cervical carcinoma, Anal cancer

Non-small cell lung cancer, Breast carcinoma, Ovarian carcinoma, Prostate carcinoma, Gastric cancer, Pancreatic carcinoma, Melanoma

Hepatocellular carcinoma, Melanoma, Prostate cancer, Sarcoma

Urothelial carcinoma, Sarcoma, Non-small cell lung cancer, Melanoma

Solid Tumors – Potentially all carcinomas

Amgen Collaboration Targets

Heme Malignancies and Solid Tumors (AML, renal cell carcinoma and MM)

TARGET TUMOR TYPES

Heme Malignancy Solid Tumors

18 K I T E P H A R M A , I N C .18

Compelling Evidence of Broad Anti-Tumor Activity in B Cell Malignancies

• 32 patients enrolled (29 evaluable), largest dataset of anti-CD19 CAR in lymphoma

• Response Rate 76% overall, 65% in DLBCL/PMBCL (n=17)

• 16 patients with ongoing response

• 12 patients with ongoing response over 1 year

• Emerging AE profile includes:− Transient cytokine release syndrome− Reversible neurotoxicity− B cell aplasia

• Ongoing clinical studies to optimize cell number and conditioning regimen

Kochenderfer Blood 2012; Kochenderfer JCO 2015; Kochenderfer ASH 2014

19 K I T E P H A R M A , I N C .19

Anti-CD19 Treatment Achieves Complete Responses in Heavily Pretreated Patients with ALL

Lee et al Lancet 2015

Intention-to-TreatAnalysis

ALL (N=20)

Complete Response 14 (70%)

MRD negative Complete Response

12 (60%)

Allogeneic Transplant 10 (50%)

Relapse Post Allogeneic Transplant

0 (0%)

78.8%

51.6%

Median follow up = 10 mo

20 K I T E P H A R M A , I N C .20

KTE-C19-101Phase 1/2 Trial in Refractory Aggressive NHL

Cohort 2: PMBCL and TFL(n=40)

Cohort 1: DLBCL(n=72)

DLBCL=Diffuse Large B-cell LymphomaPMBCL=Primary Mediastinal B-cell LymphomaTFL=Transformed Follicular Lymphoma

Pivotal Phase 2• Key Eligibility Criteria

− Refractory DLBCL, PMBCL, TFL− Measurable Disease− ECOG 0-1

• Primary Endpoint− Objective Response Rate

• Operations− First patient treated with KTE-C19

1H 2015− Multi-center study (~25 sites)− Interim analysis (cohort 1) after 50

patients − Plan to file for accelerated

approval if compelling data

21 K I T E P H A R M A , I N C .21

KTE-C19 Will Address Significant Unmet Needs in B Cell Malignancies

INDICATION POPULATIONFIRST SUBJECT

ENROLLEDDEATHS/YEAR*

DLBCLPMBCL

TFL

Refractory or relapsed post transplant

1H 2015 ~10,000

MCL Relapsed/refractory 2015 ~1,200

ALL Relapsed/refractory 2015 ~1,400

CLL Relapsed/refractory 2015 ~4,600

*US death per year

22 K I T E P H A R M A , I N C .22

Rapid and Efficient eACT ™ Manufacturing for KTE-C19 at Clinical and Commercial Scale

Apheresis product

Gene Transduction

Cell Expansion

Cryopreservation

T Cell Activation

Ready for bedside use

• cGMP facility in Santa Monica, CA and in Amsterdam

• Commercial facility near LAX airport

PROCESS CAPABILITIES

23 K I T E P H A R M A , I N C .23

Commercial Manufacturing Facility – Kite Pharma

24 K I T E P H A R M A , I N C .24

Commercial Manufacturing Facility – Kite Pharma

25 K I T E P H A R M A , I N C .25

Advancing Next Generation eACT™ Technology

• Lineage-specific targets (Heme malignancies)

• Cancer-specific (CTAg, VAg, NAg) vs. Cancer-associated antigens

Target Selection

• Human scFv; linker-spacer; co-stimulatory domain

• High affinity TCR

• Additional stimulatory signals

CAR/TCR Optimization

• Limited ex vivo T cell expansion

• Selected expansion of T cell subtypesManufacturing

• Combination therapyTumor

Microenvironment

• CRITICAL for T cell expansionConditioning

Chemotherapy

26 K I T E P H A R M A , I N C .26

Milestones for the Next 12 Months

KTE-C19 IND accepted by FDA

Secure in-house clinical manufacturing site

Establish European presence

Build out commercial manufacturing capacity

Treat first patient with KTE-C19 in a pivotal phase 1/2 clinical trial for refractory DLBCL

• Initiate additional KTE-C19 studies in MCL, ALL, and CLL

• Obtain Breakthrough Therapy Designation in DLBCL

• Present KTE-C19 data

• File an IND relating to a TCR product

27 K I T E P H A R M A , I N C .27

Expected Data Flow

Program1 Indication Data Availability2

Anti-CD19 CAR B Cell Malignancies periodic update

KTE-C19 CAR

DLBCLP1 2015P2 2016

MCL TBD

ALL TBD

CLL TBD

EGFRVIII CAR GBM 2016

NY-ESO-1 TCR Solid Tumors 2016

MAGE A3/A6 TCR Solid Tumors 2016

MAGE A3 TCR Solid Tumors 2016

HPV-16 E6 TCR Cervical, H&N 2016

HPV-16 E7 TCR Cervical, H&N 2016

1Other than KTE-C19, clinical trials being conducted by the NCI pursuant to the CRADA2Anticipated dates for initial data availability are provided

28 K I T E P H A R M A , I N C .28

Kite Pharma’s Competitive Advantages for Building the Future of Cancer Immunotherapy

STRATEGIC PARTNERS

(NCI/Amgen)

FIRST NHL MULTICENTER

TRIALS

PROPRIETARY MANU-

FACTURINGPROCESS

SOLID IPTHROUGH 2027

WELL FINANCED

BEST TEAM

BREAK-THROUGH EFFICACY

ROBUSTPIPELINE

(CAR & TCR)

29 K I T E P H A R M A , I N C .29

Join us on June 23rd for Kite Investor Day

30 K I T E P H A R M A , I N C .30

THANK YOU